News thumbnail
Health / Sun, 15 Nov 2026 healthcare-in-europe.com

Beta-D-glucan testing: More than a single result

Image courtesy of Prof. MontesinosProf. Montesinos works at the intersection of routine clinical microbiology and research, with a particular focus on the diagnosis of invasive fungal infections (IFIs). Within this field, BDG testing occupies a well-defined role. ‘I mainly use it as a complementary biomarker rather than as a stand-alone test,’ she explains. In these settings, the non-invasive nature of serum BDG testing is a significant practical advantage. Interpretation must always take account of the broader clinical and microbiological picture.

Image courtesy of Prof. Montesinos

Prof. Montesinos works at the intersection of routine clinical microbiology and research, with a particular focus on the diagnosis of invasive fungal infections (IFIs). Within this field, BDG testing occupies a well-defined role. ‘I mainly use it as a complementary biomarker rather than as a stand-alone test,’ she explains. ‘Its value lies in combining the result with the patient’s clinical context and with other microbiological tools, such as fungal culture, species-specific biomarkers and molecular methods.’

Her clinical experience with BDG has centred on three conditions in particular: Pneumocystis jirovecii pneumonia (PJP), candidaemia and invasive aspergillosis – each of which presents a distinct diagnostic challenge and calls for a different approach to BDG interpretation.

Where BDG adds the most value

BDG is particularly useful in immunocompromised and clinically fragile patients – those with haematological malignancies, transplant recipients, and patients receiving immunosuppressive therapies – where obtaining invasive respiratory samples such as bronchoalveolar lavage (BAL) may be difficult, contraindicated, or simply not feasible. In these settings, the non-invasive nature of serum BDG testing is a significant practical advantage.

A further strength is its broad, panfungal spectrum. ‘BDG can support the suspicion of an invasive fungal infection without prior knowledge of the causative organism,’ Prof. Montesinos notes, ‘making it a useful complementary tool alongside more specific biomarkers.’ However, sensitivity and negative predictive value vary across clinical settings and fungal infections, and a negative BDG result cannot always completely exclude an IFI, she points out. Interpretation must always take account of the broader clinical and microbiological picture.

© All Rights Reserved.